Long-Term Safety and Effectiveness of Adalimumab for Moderate to Severe Psoriasis: Results from 7-Year Interim Analysis of the ESPRIT Registry
Sign Up to like & getrecommendations! Published in 2017 at "Dermatology and Therapy"
DOI: 10.1007/s13555-017-0198-x
Abstract: IntroductionESPRIT (NCT00799877) is an ongoing 10-year international prospective observational registry evaluating the long-term safety and effectiveness of originator adalimumab in routine clinical practice for adult patients with chronic plaque psoriasis. Herein, we report the long-term… read more here.
Keywords: long term; safety; safety effectiveness; term safety ... See more keywords